Rankings
▼
Calendar
PCRX Q1 2024 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena
PCRX
Pacira BioSciences, Inc.
$971M
Q1 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$167M
+4.2% YoY
Gross Profit
$120M
71.6% margin
Operating Income
$13M
7.9% margin
Net Income
$9M
5.4% margin
EPS (Diluted)
$0.19
QoQ Revenue Growth
-7.8%
Cash Flow
Operating Cash Flow
$49M
Free Cash Flow
$46M
Stock-Based Comp.
$13M
Balance Sheet
Total Assets
$1.6B
Total Liabilities
$691M
Stockholders' Equity
$892M
Cash & Equivalents
$184M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$167M
$160M
+4.2%
Gross Profit
$120M
$111M
+7.5%
Operating Income
$13M
-$3M
+527.4%
Net Income
$9M
-$20M
+146.0%
Revenue Segments
Product
$166M
51%
EXPAREL
$132M
41%
ZILRETTA
$26M
8%
Bupivacaine Liposome Injectable Suspension
$3M
1%
← FY 2024
All Quarters
Q2 2024 →